Clinical Trial Search

Primary: Self-reported Seizure Frequency — 6.4 seizure days per 4 weeks

Primary: Safety and Tolerability of Low Frequency Stimulation of the Fornix With Regards to Memory Function — 0; 0 Participants

Primary: Functional Connectivity

Primary: Incidence of Qualifying Adverse Events — 7.9 percentage of participants

Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04

Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants

Primary: The Change Scores in Memory Measures From Baseline to Post-treatment/Placebo Will be Compared Between the Memantine Treatment and Placebo Groups. — 1.00; 1.78; 4.38…

Primary: Change in Seizure Frequency Expressed as the Average Number of Seizures Experienced by All Participants and Recorded at Specified Time Points Throughout the Study…

Primary: Primary Analysis: Change in Seizure Rate — -40.4; -14.5 Percentage change from baseline — p=0.0017

Primary: 50% Responder Rate After Active rTMS Treatment Compared With Placebo Treatment — 0; 0; 0; 0 participants

Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05

Primary: To Determine if the Frequency of Premenstrual Dysphoric Disorder Differs Among Various Antiepileptic Drug Monotherapies. — 0; 0; 0; 2 Participants

Primary: Completed MEG — 1 participants

Primary: Number of Seizure After Treatment by tDCS — 80.67; 93.43; 35.53; 93.14 seizures — p=<0.05

Primary: Change From Baseline in the Mean Number of Daily Seizures at 1 Year. — 9 Number of Seizures — p=<0.02

Primary: Number of Participants With Evaluable fMRI Scans — 9; 9; 9; 9 participants

Primary: Adherence to Intervention — 2; 0; 0 Participants

Primary: Z-score Gamma Power in Amygdala Per Valence Category — 1.21; 1.88; 1.24 z-score

Primary: Hippocampal Activity (Arterial Spin Labeling [ASL] Study) After Levetiracetam (LEV) — 28.3; 27.1; 28.0; 28.5 ml/100g/min

Primary: Number of Participants Who Were Seizure Free in the Maintenance Phase (Across Seizure Types and by Seizure Type Within 6 Months Prior to the Start of the Study) — 28…

Primary: Post-Traumatic Epilepsy — 6; 8 participants

Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days

Primary: Heartbeat Evoked Potential (HEP) for Attention — -1.5 µV

Primary: Intensity of the MRI Signal in the Left Temporal Precentral Zone — 1.06; 1.04 ratio

Primary: Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level — 0 percentage of participants

Primary: Depression Severity — 22.5; 12.0; 14.1 score on a scale — p=0.04

Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]

Primary: Change in Montgomery Asberg Depression Rating Scale (MADRS) — 16.75; 22.94; 11.21; 21.81 score on a scale — p=0.036

Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001

Primary: Number of Patients With Adverse Events — 0; 0 Participants